Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05150236
Title 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Indications

prostate cancer

prostate adenocarcinoma

Therapies

Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab

lutetium Lu 177 vipivotide tetraxetan

Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.